A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the
A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the third quarter for the NeuroQ software, which rapidly and automatically quantifies more than 200 standardized regions of interest. It compares activity in those brain regions to regional activity values derived from a database of normal scans.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
FDA Clears MRI-Based AI Segmentation of Organs at Risk During Radiation Therapy
May 2nd 2025Capable of segmenting over 37 organs and structures in the head, neck and pelvis, the MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.